Abbott Laboratoris
Recent News About Abbott Laboratoris
-
Abbott's CardioMEMS HF system Receives FDA Approval to Support Patients Battling Earlier-Stage Heart Failure
Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the company's CardioMEMS™ HF System to support the care of more people living with heart failure. With the expanded indication, an additional 1.2 million U.S. patients1 are now eligible to benefit from advanced monitoring with the CardioMEMS sensor, which marks a significant increase over the current addressable population.
-
Abbott Announces World's First Implant of Dual-chamber Leadless Pacemaker in Pivotal Trial
ABBOTT ANNOUNCES WORLD'S FIRST IMPLANT OF DUAL-CHAMBER LEADLESS PACEMAKER IN PIVOTAL TRIAL
-
Abbott receives U.S FDA Clearance for New Cardiac Mapping System to improve how Doctors Treat Abnormal Heart Rhythms
Abbott today announced it has received clearance from the U.S. Food and Drug Administration for the EnSite™ X EP System with EnSite Omnipolar Technology (OT), a new cardiac mapping platform available in the U.S. and across Europe that is designed to help physicians better treat abnormal heart rhythms, also known as cardiac arrhythmias.